Cell-free DNA (cfDNA) Reference Materials
Building confidence in the results of Liquid Biopsies – authentic cfDNA reference samples for an improved quality assurance
Reference materials for accurate ctDNA detection in cfDNA assays
Ensure Reliable Liquid Biopsy Results
Our advanced liquid biopsy platform combines digital PCR (dPCR/ddPCR) and next-generation sequencing (NGS) technologies to achieve ultra-sensitive ctDNA detection. Rigorous quality control protocols minimize false positives/negatives, ensuring clinical-grade accuracy for informed treatment decisions and research reproducibility.
Harmonize Testing Protocols
Clinically validated RMs address critical preanalytical variables including DNA extraction efficiency optimization Precise concentration quantification Fragment size distribution analysis SNV detection across VAF ranges (0.01%-5%) These standardized controls reduce inter-lab variability in ctDNA analysis, ensuring comparable results across clinical trials and diagnostic settings while enhancing treatment response monitoring and prognostic accuracy.
Standardize Cross-Platform Consistency
Reference Materials (RMs) derived from cancer cell lines enable precise benchmarking of ctDNA detection methods. These characterized controls facilitate assay validation, sensitivity optimization (down to 0.1% VAF), and systematic bias identification, essential for translating research findings into clinical applications while maintaining reproducibility across laboratories.
cfDNA Reference Materials
Unmatched Customizability & Open Production Process
- Broad Range of cfDNA RMs – We produce diverse cfDNA RM types, supporting applications from early-stage research to clinical validation.
- Controlled cfDNA Fragmentation – Choose from various cfDNA size populations to match physiological conditions.
- Extensive Variant Selection – Wide-ranging SNVs to enhance assay validation.
- Epigenetic Profiling – RMs with different methylation patterns for epigenetic studies.
- Copy Number Variations (CNVs) – Designed for robust CNV detection and analytical validation.
True Cancer-Specific cfDNA for Clinical Relevance
- Authentic cfDNA with Cancer-Specific Signatures – Produced using cancer cell lines to ensure biologically relevant reference materials.
- Diverse Sample Origins – Flexibility in choosing cfDNA from various cancer and non-cancer cell lines to align with research objectives.
- Select from synthetic, naturally degraded, mechanically fragmented, or enzymatically processed cfDNA for optimal assay performance.
- High-Concentration Mutant cfDNA (ctDNA) - Enables extended and cross-platform validations using consistent lot samples.
- Flexible cfDNA Analysis Modalities – Our materials support sub-nucleosomal, mono-nucleosomal, and long cfDNA characterization for diverse analytical applications.
Affordable & Scalable Solutions
- Optimized Production for Cost-Effectiveness – Our streamlined processes ensure competitive pricing while maintaining premium quality.
- Scalability for Large-Scale Studies – High-volume production capabilities meet the needs of both small research labs and large clinical applications.
- Compatible with various NGS, qPCR, and digital PCR platforms.
Driving Oncology Innovation Through Reliable Detection
Our cfDNA reference materials are designed to support regulatory submissions, method validation, and
proficiency testing for emerging liquid biopsy assays.
Get in Touch
Connect with us to order our cfDNA reference materials or explore how we can help you achieve your goals.